

PRELIMINARY STUDY OF A NEW ANTI-DEPRESSANT DRUG

ARNOLD J. FRIEDHOFF, M.D.,¹ FRANCES A. LYNN, M.N.,¹
GILDA ROSENBLATT, M.S.¹ AND ALAN HOLDEN, M.D.¹

Recently, with the reintroduction of iproniazid as a "psychic energizer," a great deal of interest has been stimulated in the chemical treatment of seriously depressed patients. The search for effective agents for the treatment of depression has been encouraged by the failure of tranquilizers to provide relief in most severe depressions. Preliminary studies with 2-amino-1-(3,4-methylene-dioxyphenyl)-propane hydrochloride (SKF #5) (see Figure 1) led us to feel that it might be a useful drug in this area.

SKF #5 is an analog of the well known central nervous system stimulant and anorexigenic agent, dextro-amphetamine sulfate. Like the amphetamines, it has the property of increasing motor and mental activity. Unlike amphetamine, however, SKF #5 has a very considerable activity in blocking the response to a conditioned escape stimulus. This animal test appears to be one means of identifying compounds which have a potential utility in the management of behavioral changes in the mentally disturbed human. To date, this property has been associated only with agents which have some central depressant activity as well. However, the data on SKF #5 suggests that its effect on a conditioned response is not directly related to generalized depression or stimulation of the central nervous system.

Previous studies in animals (3) and in human subjects (1, 2) indicated that this drug did not produce serious toxic or side effects. The LD₅₀ in rabbits was found to be 20 mg./kg. intraperitoneally, and by oral administration in rats was 50 mg.-350 mg./

kg. This represents about one-half the toxicity of dextro-amphetamine sulfate.

On the basis of these activities in animals and in a small group of humans, it was felt that SKF #5 merited further trial in a group of schizophrenic patients to determine its tranquilizing properties, and in a group of seriously depressed patients to determine its effectiveness in altering mood.

OBJECTIVES

In a preliminary investigation of this nature, in which expectations of drug efficacy are largely unknown, it was felt that thorough study of smaller groups of patients by as objective an approach as possible was preferable to a large double-blind study. Our intentions were to obtain evidence of efficacy, if any, to derive information on dose range and optimal dose, and to elicit all possible side effects developing during a one-to-four week period of drug usage.

METHOD

All new admissions, in whom the appropriate diagnosis was concluded by two psychiatrists to be unequivocal, were included in the study if they met the following criteria:

1. Their age was between 14 and 65.
2. They had no observable serious physical abnormalities after a physical and laboratory examination.

The patients who were selected were placed on placebo for from three to seven days to offset the effects of prior drugs, to eliminate patients who recover quickly and spontaneously, and to establish a baseline of vital signs and somatic complaints.

In order to objectify as much as possible clinical impressions of patients, an evaluation scheme was established which permitted

¹Department of Psychiatry and Neurology, New York University College of Medicine, and Bellevue Hospital, Psychiatric Division.




FIG. 1. Structural formula of SKF #5

estimation of the patients' progress from a number of different viewpoints.

1. The patients were evaluated daily by a psychiatrist who made a record of improvement relative to the patient's condition on admission. His function was also to evaluate the patient's physical status and any side effects elicited by him or reported by the nurse assigned to the project.

2. A weekly evaluation was made by means of a 38-item rating scale devised for this study and based on the mental status examination. This was scored by a second psychiatrist, independently of the first psychiatrist's clinical impression, and also without reference to ratings in prior weeks.

3. The hygiene, appearance, relationships, and participation of the patient were rated daily by a psychiatric nurse, whose sole function was to observe the patient and to dispense medication.

4. Psychological tests were obtained on a limited number of patients.

5. Laboratory studies were run once a week, with the first tests done before initiation of drug treatment. The routine tests run in this study consisted of:

Complete blood count

Urinalysis, including determination of bile and urobilinogen

Cephalin flocculation

Alkaline phosphatase

Serum bilirubin

DEFINITION OF TERMS

I. Diagnosis

A. Category

Diagnoses follow the official classification of the American Psychiatric Association.

B. Chronicity

1. *Chronic*: This refers to patients who have a history of their present illness for periods exceeding six months prior to admission.

2. *Acute*: This refers to patients in whom there was no history of present illness prior to six months ago.

II. Clinical Results (Mental Status)

Severe:² Seriously disturbed, withdrawn, or depressed; may be incapacitated by delusions or thinking difficulties. Virtually completely dominated by illness.

SCHIZOPHRENIC STUDY

A total of 32 schizophrenic patients were treated for from six to fifty-four days, with doses ranging from 15 to 225 mg. Only two of these patients evidenced significant clinical improvement. No significant change in either mental status or ward behavior was noted in the other 30 patients. Most of the patients appeared to be somewhat more alert and energetic. However, this effect was insufficient to be reflected in their ratings. The data on these schizophrenics was not subjected to statistical analysis because of the obvious ineffectiveness of the drug on inspection of the results. These results are summarized in Table 1.

² All patients in this study were considered to be severely ill.

DEPRESSION STUDY

A total of 25 seriously depressed patients were placed on SKF #5 for periods between ten and forty-two days, with doses ranging from 30 to 300 mg. In one group, time, another group of patients was placed on placebo. Two patients were in the drug group for each patient in the placebo group, resulting in a total group of 25 patients on active drug and 25 patients on placebo. Both drug and placebo groups were treated for an average of 21 days with a range of from ten to 42 days. A description of the patients is given in Table 2.

RESULTS

An analysis of changes in total scores demonstrated a significant difference between the scores of patients on the drug and placebo groups. The mean score of patients on the drug group was 13.1 initially, to 8.7 after treatment. On the placebo group, the mean score was 13.1 initially, to 13.1 after treatment. A lower score indicates a better mental status. The mean score of the patients on the drug group was unchanged (see Table 3). The difference between the initial scores indicated a significant difference in the course of illness between the drug and placebo groups before treatment. The mean score of the drug group was significantly lower (P < .01). Analysis of the results of each group with regard to duration of illness, severity, age, or sex showed no significant differences do not significantly influence the results. This statistical difference is in accord with a clinical improvement in 76 per cent of the patients on the drug group as compared with 24 per cent of the patients on the placebo group.

In addition, seven patients were placed on drug to placebo and back to drug. In this group, five patients improved on drug administration and the other two improved on placebo. In three to five days on placebo, the patients were readministered drug and showed improvement of all five patients.

TABLE 1

Results of Treatment of Schizophrenic Patients

Total No. Of Patients	Mean Maximum Dose	Mean Days On Drug	Results		Per cent Improved
			Im-proved	Unim-proved	
32	88 mg.	23	2	30	6

DEPRESSION STUDY

A total of 25 seriously depressed patients were placed on SKF #5 for periods varying between ten and forty-two days, with doses ranging from 30 to 300 mg. At the same time, another group of patients were placed on placebo. Two patients were assigned to the drug group for each patient assigned to the placebo group, resulting in a final group of 25 patients on active drug and 12 on placebo. Both drug and placebo groups were treated for an average of two weeks, with a range of from ten days to six weeks. A description of the patients is summarized in Table 2.

RESULTS

An analysis of changes in the rating scale scores demonstrated a significant drop in the scores of patients on the drug—from 13.1 initially, to 8.7 after treatment. On this scale a lower score indicates improvement. The mean score of the patients on placebo was unchanged (see Table 3). A comparison of the initial scores indicates that there was no significant difference in the severity of illness between the drug and the placebo groups before treatment. The large change in the score of the drug group after treatment is statistically significant (t test: $P < .01$). Analysis of the differences in each group with regard to diagnosis, chronicity, severity, age, or sex indicates that these differences do not significantly influence the results. This statistical data is in accord with a clinical impression of improvement in 76 per cent of the drug group, as compared with 24 per cent of the placebo group.

In addition, seven patients were rotated from drug to placebo and back to drug. Of this group, five patients improved during drug administration and then relapsed in three to five days on placebo. Subsequent readministration of drug resulted in improvement of all five patients. The other

TABLE 2
Classification of Depressed Patients

	Number of Patients			
	Drug Group		Placebo Group	
	No.	%	No.	%
<i>Diagnosis</i>				
Schizophrenic Reaction, Schizoaffective Type	4	16	2	17
Involuntional Psychotic Reaction	12	48	4	33
Psychotic Depressive Reaction	3	12	3	25
Manic Depressive Reaction	1	4	0	0
Neurotic Depressive Reaction, Severe	5	20	3	25
<i>Chronicity</i>				
Acute	12	48	7	58
Chronic	13	52	5	42
<i>Sex</i>				
Male	6	24	2	17
Female	19	76	10	83
<i>Mean Age</i>	47		49	
Total Number of Patients	25		12	

TABLE 3
Results of Treatment of Depressed Patients

Group	No. of Patients	Number Improved	Mean Rating Scale Scores	
			Pre-Treatment	Post-Treatment
Drug	25	19 (76%)	13.1	8.7
Placebo	12	3 (24%)	14.4	14.4

two patients improved on drug, but did not relapse after two weeks on placebo.

Four of the depressed patients in the study subsequently had electric shock treatment, either after withdrawal of the drug and relapse, or because of failure to improve on the drug. One of the four improved on the drug and, also, later improved on EST. Three of the patients treated were unimproved on the drug and only one of these subsequently improved on shock treatment.

Inasmuch as it was not possible at the time of the study to maintain patients on

this medication at home, it was necessary to discontinue treatment on all patients. Most patients tended to relapse after discontinuation of the drug and, therefore, required further hospitalization. As a result, a comparison of the final disposition of patients in the drug group and in the placebo group is not meaningful.

The three following case histories will illustrate the clinical findings, and course, in two patients who improved as a result of treatment with SKF #5 and one patient who did not improve.

Case 1. A 57 year old, unmarried woman was brought to the hospital at the suggestion of her physician. In the past few months she had complained of increasingly severe "burning" in the stomach and "whirling in the head." She had been unable to sleep and her appetite was poor. Prior to the onset of these symptoms she had been working and had had no history of previous episodes.

In the hospital she was depressed and agitated, and complained that she had not moved her bowels for two weeks and that her stomach burned. She stated repeatedly that she had "not done enough" to help her ill sister. Physical examination was non-contributory.

A diagnosis of involuntional psychotic reaction was made and treatment was begun with SKF #5, 50 mg., t.i.d. In two days the patient admitted to bowel movements, and her agitation was lessened. Therapy was continued for 19 days, with a maximum dose of 75 mg., t.i.d. At the end of that time depression was not evident, and she was eating and sleeping well. Relapse did not occur on withdrawal of drug, and the patient was discharged.

The Rating Scale changed from an initial value of 11 to a low of 1 at termination of treatment. No side effects other than dilated pupils were noted.

Case 2. The patient, a 38 year old married woman, was admitted to the hospital after

her husband noted that she had been depressed and tearful for one month. The first episode of depression had occurred 15 years ago and cleared after three month's hospitalization without specific treatment. Since that time she had had periodic mild depressions, but was first hospitalized two months prior to her present admission. At that time she had received eight electric shock treatments and was discharged much improved. After several weeks, however, she again became depressed. She has never had manic episodes.

On examination the patient appeared depressed, tearful and retarded. She was preoccupied with ideas of suicide. She stated that she could not sleep or eat. No delusions or hallucinations were evident, and the patient's sensorium was clear.

A diagnosis of manic depressive reaction, depressed type, was made and treatment was begun with 25 mg. of SKF #5, t.i.d. After several days the dose was increased to 50 mg., t.i.d. With this increase the patient appeared less tense and more relaxed, but remained depressed. A further increase in dose to 75 mg., t.i.d., resulted in clearing of symptoms. The patient reported that she felt well and that her appetite and sleep were restored to normal.

Medication was discontinued on the 12th day of treatment. After two days the patient's original symptoms returned. Medication was reinstated, and in one week she again improved. When medication was again discontinued, the patient again relapsed. Since it was not possible to continue her on this treatment outside the hospital, she was referred for EST. After 14 treatments she was much improved and was discharged.

The Rating Scale changed from a high of 13 to zero at the peak of improvement. The only side effect noted was mild drowsiness.

Case 3. A 56 year old unmarried woman was admitted to the hospital in a state of agitation and depression. She had been hospital-

ized four years ago with an depression, but was discharged weeks without specific treatment.

The present episode started prior to her present admission. At the time she began to lose her appetite she was unable to sleep. Before the onset of symptoms, she had been working as a seamstress. Gradually, she began to feel depressed and became agitated. At the time of admission she was on the floor and appeared depressed and apprehensive. She stated "I'm dying from an incurable disease. My mouth feels like smoke is coming out of it." The patient had many physical complaints. Her sensorium was clear.

A diagnosis of involuntional psychotic reaction was made and treatment was begun with 15 mg. of SKF #5, t.i.d. The dose was increased to 50 mg. over a period of 10 days, with no apparent improvement in status. No side effects other than dilated pupils were noted. Because of the patient's intense depression it was decided to discontinue drug and institute electric shock therapy. She had six treatments over the next two weeks, without any improvement. After the shock therapy she developed mental impairment and other organic symptoms. Medication was discontinued and she was ultimately transferred to a state hospital.

Rating Scale scores changed from a pre-treatment value of 16 to a post-treatment value of 18.

TOXICOLOGICAL EFFECTS AND LABORATORY STUDIES

Alkaline phosphatase was determined during the drug treatment in all patients. In one patient the alkaline phosphatase decreased during the drug treatment. In the other patients of the twelve patients who had elevated alkaline phosphatase values, the values decreased further, and in three of these patients the levels returned to normal in three weeks.

ed that she had been de-
ful for one month. The
epression had occurred 15
leared after three month's
ithout specific treatment.
she had had periodic mild
was first hospitalized two
her present admission. At
ad received eight electric
and was discharged much
veral weeks, however, she
ressed. She has never had

the patient appeared de-
nd retarded. She was pre-
eas of suicide. She stated
t sleep or eat. No delusions
were evident, and the pa-
was clear.

manic depressive reaction,
was made and treatment
25 mg. of SKF #5, t.i.d.
s the dose was increased to
ith this increase the pa-
ss tense and more relaxed,
ressed. A further increase
, t.i.d., resulted in clearing
e patient reported that she
at her appetite and sleep
normal.

s discontinued on the 12th
. After two days the pa-
mptoms returned. Medi-
stituted, and in one week
ed. When medication was
d, the patient again re-
as not possible to continue
ment outside the hospital,
for EST. After 14 treat-
ch improved and was dis-

le changed from a high of
eak of improvement. The
oted was mild drowsiness.

old unmarried woman was
ospital in a state of agita-
n. She had been hospital-

ized four years ago with an episode of de-
pression, but was discharged after several
weeks without specific treatment.

The present episode started two months
prior to her present admission, at which
time she began to lose her appetite and was
unable to sleep. Before the onset of these
symptoms, she had been working full time
as a seamstress. Gradually, she had begun
to feel depressed and became tearful and
agitated. At the time of admission she paced
the floor and appeared depressed, tearful
and apprehensive. She stated repeatedly,
"I'm dying from an incurable illness . . . and
my mouth feels like smoke is coming from
it." The patient had many other somatic
complaints. Her sensorium was clear.

A diagnosis of involuntional psychotic re-
action was made and treatment was begun
with 15 mg. of SKF #5, t.i.d. Dosage was
increased to 50 mg. over a period of eight
days, with no apparent improvement in
status. No side effects other than dry mouth
and dilated pupils were noted. However,
because of the patient's intense agitation,
it was decided to discontinue drug treatment
and institute electric shock treatment. She
had six treatments over the course of two
weeks, without any improvement. During
the shock therapy she developed memory
impairment and other organic signs. Treat-
ment was discontinued and the patient was
ultimately transferred to a state hospital.

Rating Scale scores changed from an ini-
tial value of 16 to a post-treatment value
of 18.

TOXICOLOGICAL EFFECTS AND LABORATORY STUDIES

Alkaline phosphatase was noted to rise
during the drug treatment in twelve pa-
tients. In one patient the alkaline phospha-
tase decreased during the drug trial. Five
of the twelve patients who developed ele-
vated alkaline phosphatase were followed
further, and in three of these patients the
levels returned to normal in from one to
three weeks.

No other evidence of liver involvement
was noted in these patients.

The most persistent side effects were di-
lated pupils and dry mouth on higher doses.
Other side effects felt to be related to the
drug were mild tremors, drowsiness usually
during the first few days of treatment, and
transient anorexia and insomnia. One pa-
tient developed an itching erythematous
dermatitis, which disappeared when the
drug was withdrawn. This was felt to be an
allergic drug reaction. One patient devel-
oped marked flushing and sweating when
the dose was raised to 300 mg. On subse-
quent lower doses this did not appear. An-
other patient had a grand mal seizure after
one dose of 30 mg. No history of previous
seizures was elicitable. After a second dose
on a subsequent day, however, no seizure
occurred. The relationship of this seizure to
drug ingestion is indefinite. EEG studies of
the patient were negative.

Repeated weight determinations were
made on 24 patients receiving the drug.
Twelve patients lost from one to 8½
pounds, for a mean loss of four pounds over
a mean time of 18 days. Eight patients
gained from 2½ to 9 pounds, for a mean
gain of five pounds over a mean time of 20
days. Four patients maintained a constant
weight. No correlation existed between
weight change and improvement.

In general, blood pressures tended to
drop slightly for the first few days on the
drug, but then returned to their base line
levels which were maintained throughout
the balance of the study.

PSYCHOLOGICAL TESTS

Improved performance on the Wechsler-
Bellevue Intelligence Scale, Form I, was
noted in some patients receiving the drug.
In general, correlation with clinical results
was low. Many problems exist in the use
of psychological tests for evaluating im-
provement with drugs, however, and a dis-
cussion of these problems is not within the
purview of this paper.

DISCUSSION

This drug appears to be of little value in the treatment or tranquilization of schizophrenics. Even in the higher dosage ranges results were few, while the number of side effects increased. The six per cent of the schizophrenics who improved during the study is consistent with what would be expected from hospitalization alone.

The 76 per cent of the depressed patients who improved on the drug constitute a significant number over that of the 24 per cent who improved on placebo. Inasmuch as this improvement was determined by three independent approaches, and as improvement was also noted in the patients' ward behavior, it is felt that this drug is effective in the treatment of some seriously depressed patients.

Further evidence of the efficacy of SKF $\times 5$ is seen in the results of the rotation studies. The close correlation between remission and drug administration, and relapse and placebo administration, confirms the effectiveness of the drug. Furthermore, without reference to rating scales, 76 per cent improvement in the drug group of seriously depressed patients is far in excess of what would be expected from spontaneous remission, hospitalization, or other extraneous factors, in a short period of time.

The quality of response, however, is also important. In general, patients' sleep and appetite improved, and apprehension diminished. This occurred despite the close relationship of this drug to the anorexigenic and sleep-inhibiting amphetamines. Nonetheless, the patients who recovered could not be considered cured in the sense that symptoms had entirely cleared. While the subjective feeling of depression and restlessness or retardation disappeared, most of the improved patients appeared tense. Furthermore, withdrawal of the drug usually led to relapse in from three to five days.

Whether this tense appearance was due to the drug, or was a residuum of the patient's illness, was difficult to establish. The dilated pupils usually accompanying the use of the drug lent further to this appearance of tension.

The effective dose range appears to be from 60 to 300 mg. per day in divided doses. Initial doses as low as 25 to 30 mg. per day should be given, as initiation of treatment with high doses frequently produced marked tension and apprehension.

The increased alkaline phosphatase and cephalin flocculation in several patients should be further evaluated in longer-range studies.

None of the side effects were of such nature as to interfere with the use of SKF $\times 5$ with either in-patients or out-patients.

SUMMARY

1. In this controlled study thirty-two schizophrenic patients were given various doses of SKF $\times 5$ without significant improvement.

2. Twenty-five seriously depressed patients were treated with this drug and improvement was noted in 76% of the group.

3. The development of high levels of alkaline phosphatase in twelve patients suggests that further appraisal of these findings should be done in a longer range study.

4. The observable side effects were not of a serious nature.

5. The effective dose appears to be between 60 and 300 mg. per day. Initial doses should be as low as 25 to 30 mg. per day.

REFERENCES

1. FRIEND, D. G. Peter Bent Brigham Hospital, Boston. Unpublished data, 1956.
2. HAGENAUER, F., RUDY, L. H. and HIMWICH, H. E. A comparative evaluation of two new central nervous system stimulants in severe psychoses. *J. Clin & Exper. Psychopath.*, **18**: 248-257, 1957.
3. SMITH, KLINE and FRENCH LABORATORIES, Philadelphia. Unpublished data, 1949.

EFFECT

T. L. SOURKES

One of the immediate effects of electroshock as applied is an increase in the sympathetic-adrenal system. This has long been recognized in physiological observations years ago. Weil-Malherbe was the first to report the first reliable direct evidence of adrenal medullary secretion from the application of electroshock with therapeutic intensity. A very sensitive chemical method of investigation detected a rise in the concentration of epinephrine in the blood after shock therapy (EST). This concentration persisted even in EST after administration of a barbiturate and a partial muscle paralyzing agent. The concentration of epinephrine in the blood returned to normal values while the patient was at rest and returned to normal after cessation. Although the concentration of the plasma epinephrine is modified EST its elevation is due to the use of the procedure. These findings have since been reported by Gris *et al.* (7) and by Gris *et al.*

In connection with a study conducted in this laboratory on the effects of pyrocatecholamines (F) on the behavior and psychiatric states

¹ From the Allan Memorial Institute of Psychiatry, McGill University, Montreal, Quebec. This investigation was supported by the Provincial Mental Health Board (T. L. Sourkes); and by grant from the National Research Fund for Research in Psychiatry (Squibb and Sons of Canada, Dr. R. A. Cleghorn). The assistance of Dr. H. V. Durost was possible to study at the Protestant Hospital (Griffiths) and Miss C. Lemieux lent valuable assistance. The authors wish to thank Dr. H. V. Durost for his interest and encourage-